Infinity Pharmaceuticals One possible earnings short-squeeze trade in the biotechnology and drugs complex is Infinity Pharmaceuticals ( INFI), which is set to release numbers on Tuesday after the market close. This company engages in the discovery and development of medicines for difficult-to-treat diseases. Wall Street analysts, on average, expect Infinity Pharmaceuticals to report revenue of $27.53 million on a loss of 38 cents per share. If you're looking for a strong, uptrending, heavily shorted biotech stock ahead of its earnings report, then make sure to check out shares of Infinity Pharmaceuticals. This stock has been on an absolute tear this year with shares up over 80%, and its currently trading just a few points off its 52-week high of $18.37 a share. The current short interest as a percentage of the float for Infinity Pharmaceuticals is very high at 23.6%. That means that out of the 16.35 million shares in the tradable float, 2.81 million shares are sold short by the bears. The short-sellers have also been increasing their bets from the last reporting period by 7.1%, or by about 185,000 shares. From a technical perspective, INFI is currently trading above both its 50-day and 200-day moving averages, which is bullish. This stock has been in a monster uptrend for the past six months, with shares soaring from a low of $5.96 to a recent high of $18.37 a share. During that uptrend, shares of INFI have consistently made higher lows and higher highs, which is bullish technical price action. That move has now pushed the stock within range of triggering a near-term breakout trade post-earnings. If you're in the bull camp on INFI, then I would look for long-biased trades after earnings if this stock manages to trigger a near-term break out above its 52-week high of $18.37 a share with high volume. Look for volume on that move that hits near or above its three-month average volume of 252,941 shares. If we get that move, then look for INFI to trade north of $20 a share post-earnings. I would simply avoid INFI or look for short-biased trades if after earnings the stock fails to trigger that breakout, and then moves back below some near-term support levels at $16.16 to $14.93 a share, and then below its 50-day moving average of $14.41 a share with heavy volume. If we get that move, then look for INFI to possibly trade down toward $13 to $12 a share post-earnings.